Work

CheckMate 648: A randomized phase 3 study of nivolumab plus ipilimumab or nivolumab combined with fluorouracil plus cisplatin versus fluorouracil plus cisplatin in patients with unresectable advanced, recurrent, or metastatic previously untreated esophageal squamous cell carcinoma.

Year: 2018

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2018.36.4_suppl.tps193

Authors: Jaffer A. Ajani, Ken Kato, Yuichiro Doki, Ian Chau, Ioannis Xynos, Agnes Balogh, Yuko Kitagawa

Institutions: The University of Texas MD Anderson Cancer Center, National Cancer Center Hospital, The University of Osaka, Royal Marsden NHS Foundation Trust, Bristol-Myers Squibb (United States), Bristol-Myers Squibb (Belgium), Keio University

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2794390470

Cites:

Cited by: 27

Related to: 10